SG11202012343TA - Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration - Google Patents
Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegenerationInfo
- Publication number
- SG11202012343TA SG11202012343TA SG11202012343TA SG11202012343TA SG11202012343TA SG 11202012343T A SG11202012343T A SG 11202012343TA SG 11202012343T A SG11202012343T A SG 11202012343TA SG 11202012343T A SG11202012343T A SG 11202012343TA SG 11202012343T A SG11202012343T A SG 11202012343TA
- Authority
- SG
- Singapore
- Prior art keywords
- onset
- progression
- age
- compositions
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862684496P | 2018-06-13 | 2018-06-13 | |
| PCT/US2019/036946 WO2019241503A1 (en) | 2018-06-13 | 2019-06-13 | Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202012343TA true SG11202012343TA (en) | 2021-01-28 |
Family
ID=68838925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202012343TA SG11202012343TA (en) | 2018-06-13 | 2019-06-13 | Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20190381071A1 (en) |
| EP (1) | EP3806862A4 (en) |
| JP (1) | JP2021527090A (en) |
| KR (1) | KR20210009422A (en) |
| CN (1) | CN112566641A (en) |
| AU (1) | AU2019285065A1 (en) |
| BR (1) | BR112020025296A2 (en) |
| CA (1) | CA3103463A1 (en) |
| MX (1) | MX2020013614A (en) |
| SG (1) | SG11202012343TA (en) |
| WO (1) | WO2019241503A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020028810A1 (en) * | 2018-08-03 | 2020-02-06 | Enterin Laboratories | Compositions and methods for treating brain-gut disorders |
| EP3829537A4 (en) * | 2018-08-03 | 2022-09-21 | Enterin, Inc. | Low dosage intranasal aminosterol dosage forms and methods of using the same |
| US11464789B2 (en) | 2018-08-03 | 2022-10-11 | Enterin, Inc. | Aminosterol compositions and methods of using the same for treating schizophrenia |
| CN110827282B (en) * | 2020-01-13 | 2020-04-10 | 南京慧脑云计算有限公司 | Brain white matter fiber tract tracing analysis method and system based on magnetic resonance imaging |
| CN111110873A (en) * | 2020-02-24 | 2020-05-08 | 苏州欣影生物医药技术有限公司 | Preparation method of magnetic resonance/nuclear medicine bimodal molecular imaging probe |
| CN111528839B (en) * | 2020-05-29 | 2023-06-23 | 北京京东方健康科技有限公司 | Sleep detection method and device, sleep assisting equipment and method |
| WO2022244929A1 (en) * | 2021-05-21 | 2022-11-24 | 애니머스큐어 주식회사 | Composition comprising inotodiol for prevention or treatment of muscular disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6143738A (en) * | 1995-06-07 | 2000-11-07 | Magainin Pharmaceuticals, Inc. | Therapeutic uses for an aminosterol compound |
| TW200927755A (en) * | 2007-09-06 | 2009-07-01 | Genaera Corp | A method for treating diabetes |
| US8623416B2 (en) * | 2009-11-25 | 2014-01-07 | Michael Zasloff | Formulations comprising aminosterols |
| US10040817B2 (en) * | 2013-10-03 | 2018-08-07 | Enterin Laboratories, Inc. | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
-
2019
- 2019-06-13 US US16/440,414 patent/US20190381071A1/en not_active Abandoned
- 2019-06-13 SG SG11202012343TA patent/SG11202012343TA/en unknown
- 2019-06-13 CA CA3103463A patent/CA3103463A1/en active Pending
- 2019-06-13 MX MX2020013614A patent/MX2020013614A/en unknown
- 2019-06-13 KR KR1020217000559A patent/KR20210009422A/en unknown
- 2019-06-13 US US17/251,322 patent/US20210252023A1/en active Pending
- 2019-06-13 AU AU2019285065A patent/AU2019285065A1/en active Pending
- 2019-06-13 WO PCT/US2019/036946 patent/WO2019241503A1/en unknown
- 2019-06-13 CN CN201980052151.2A patent/CN112566641A/en active Pending
- 2019-06-13 BR BR112020025296-4A patent/BR112020025296A2/en unknown
- 2019-06-13 JP JP2020569002A patent/JP2021527090A/en active Pending
- 2019-06-13 EP EP19818961.5A patent/EP3806862A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020025296A2 (en) | 2021-03-09 |
| KR20210009422A (en) | 2021-01-26 |
| CN112566641A (en) | 2021-03-26 |
| MX2020013614A (en) | 2021-05-27 |
| AU2019285065A1 (en) | 2021-01-07 |
| EP3806862A4 (en) | 2022-07-06 |
| WO2019241503A1 (en) | 2019-12-19 |
| CA3103463A1 (en) | 2019-12-19 |
| JP2021527090A (en) | 2021-10-11 |
| US20190381071A1 (en) | 2019-12-19 |
| US20210252023A1 (en) | 2021-08-19 |
| EP3806862A1 (en) | 2021-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202006627B (en) | Methods and compositions for treating cancer | |
| SG11202012343TA (en) | Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration | |
| EP3894392A4 (en) | Compositions and methods for the treatment of cancer | |
| IL273959A (en) | Methods and compositions for the treatment of rare diseases | |
| IL276808A (en) | Compositions and methods for cancer treatment | |
| GB2578539B (en) | Compositions and methods for preventing or treating muscle conditions | |
| IL275626A (en) | Surface treatment compositions and methods | |
| SG11202012055PA (en) | Methods and compositions for preventing or treating calciphylaxis | |
| SG11202012070YA (en) | Methods and compositions for preventing or treating tissue calcification | |
| IL280413A (en) | Bismuth-thiol compositions and methods for treating wounds | |
| SG11202103033WA (en) | Compositions and methods for the treatment of presbyopia | |
| IL285886A (en) | Compositions and methods for treating laminopathies | |
| SG11202012435UA (en) | Compositions and methods for treating cancer | |
| IL287796A (en) | Compositions and methods for the treatment of atpase-mediated diseases | |
| SG11202102442WA (en) | Methods and compositions for preventing and treating atherosclerosis and related diseases | |
| GB202001422D0 (en) | Compositions and methods for preventing or treating nephrolithiasis | |
| IL280218A (en) | Methods of treating hfpef employing dapagliflozin and compositions comprising the same | |
| IL280348A (en) | Surface treatment compositions and methods | |
| IL276203A (en) | Compositions and methods of treating cancer | |
| PT3810128T (en) | Compositions for treating and/or preventing protein-aggregation diseases | |
| IL272147A (en) | Methods and compositions for the treatment of cancer | |
| IL280262A (en) | Compositions and methods for the treatment of cancer | |
| IL285796A (en) | Methods and compositions for treating | |
| EP3987032A4 (en) | Methods and compositions for the treatment of cancer | |
| IL282948A (en) | Compositions and methods for treating cancer |